All In Biotech

Free tool

FAERS Monitor: Emrosi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219015 or its brand name (Emrosi, Minocycline Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

18

Serious

4

22% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness4
  • rash4
  • back pain2
  • gastrointestinal disorder2
  • headache2
  • product use in unapproved indication2
  • pruritus2
  • anaemia1
  • arthralgia1
  • burning sensation1
  • condition aggravated1
  • diarrhoea1
  • disturbance in attention1
  • dry skin1
  • hand dermatitis1

Reports by year received

View as table
YearReports
20258
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,141 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hand dermatitis11690.3251.2421
gastrointestinal disorder226.17.127
disturbance in attention121.73.24
burning sensation116.72.53
rashSignal410.74.527
back pain210.12.79
product use in unapproved indication29.42.68
dizzinessSignal49.43.923
dry skin18.81.31
anaemia16.10.91
pruritus26.11.64
condition aggravated13.80.60
headache23.71.02
arthralgia12.80.40
diarrhoea11.80.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.